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Abstract
The goal of nanomedicine is to transport drugs to pathological tissues, reducing side effects while increasing targeting and 
efficacy. Aggregates grafted by bioactive molecules act as the active targeting agents. Among bioactive molecules, peptides, 
which are able to recognize overexpressed receptors on cancer cell membranes, appear to be very promising. The aim of this 
study was to formulate analog peptide-labeled micelles enabled to potentially deliver highly hydrophobic drugs to cancer cells 
overexpressing epidermal growth factor (EGF) receptor (EGFR). The selected synthetic peptide sequences were anchored 
to a hydrophobic moiety, aiming to obtain amphiphilic peptide molecules. Mixed micelles were formulated with  Pluronic® 
F127. These micelles were fully characterized by physico-chemical methods, estimating the critical micellar concentration 
(CMC) by fluorescence. Their sizes were established by dynamic light scattering (DLS) analysis. Then, micelles were also 
tested in vitro for their binding capacity to human hepatocellular carcinoma (HCC) cell lines overexpressing EGFR.
Keywords Peptide · Peptide backbone structures · Drug delivery · Peptide self-assembling carriers · Active targeting 
receptors · Binding peptides · Epidermal growth factor · Epidermal growth factor receptor · Hepatocellular carcinoma
Introduction
In drug administration, two major limits are well-known: 
drug degradation and lack of selectivity. The latter is a draw-
back that can cause numerous side effects in healthy tissues. 
In addition, decreased drug bioavailability and lower per-
centages of drugs accumulated in pathological tissues are 
often observed. Another tricky issue is the poor aqueous 
solubility of many drugs. Drug loading onto nanocarriers 
can prevent these inconveniences and also facilitate delivery 
to unhealthy tissues by increasing the blood circulation time.
In recent years, several types of carriers, such as micelles, 
albumin core–shell nanoparticles (NPs) and nanostructured 
lipid carriers (NLC), have been developed to efficiently 
deliver hydrophobic drugs, including conventional chemo-
therapeutic agents, e.g., paclitaxel (PTX) (Liggins and Burt 
2002; Tang et al. 2018, Upponi et al. 2018), and targeted 
agents, e.g., Sorafenib (Cervello et al. 2017; Bondi et al. 
2015) and erlotinib (Hsu et al. 2018).
A promising nanomedicine-based technology is the use of 
polymeric micelles, which have a core–shell structure incor-
porating poorly soluble drugs that defends them from inac-
tivation in biological fluids (Torchilin, 2001). Due to their 
small particle size (< 100 nm), polymeric micelles exhibit 
many advantages that can overcome previously described 
drawbacks: better targeting ability, longer circulation in vivo 
and more effective drug delivery (Varela-Moreira, et al. 
2017; Oerlemans et al. 2010; Trubetskoy 1999).
More recently, many systems have been assessed in 
clinical trials as carriers for hydrophilic and hydrophobic 
anticancer chemotherapeutics (Varela-Moreira et al. 2017; 
Cabral and Kataoka 2014). Among the polymeric nano-
carriers, the most broadly investigated have been amphi-
philic block copolymers (Kozlov et al. 2000; Chiappetta 
and Sosnik 2007; Mohammadi et al. 2017): poly(ethylene 
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oxide)–poly(propylene oxide) (PEO–PPO–PEO), contain-
ing a hydrophobic region (poly-propyleneoxide, PPO) and 
two hydrophilic portions (poly-ethyleneoxide, PEO). At low 
concentration, this peculiar structure can self-assemble into 
spherical micelles. In addition, the PEO sterically stabilizes 
the micelles and makes them more resistant to opsoniza-
tion and to uptake by the macrophages of the reticulo-
endothelial system (RES), allowing them to circulate in the 
blood for longer (Moghimi et al. 1993). These character-
istics widely fit with non-ionic surfactant  Pluronic® F127 
(PF127), which in aqueous solution is able to aggregate in 
micelles (Kabanov et al. 2002). Physico-chemical techniques 
have established the properties of these micelles, such as 
size, shape and temperature-changing behavior dependence 
(Basak and Bandyopadhyay 2013). These properties allow 
NPs to accumulate within solid tumors in a passive target-
ing process due to the enhanced permeability and retention 
(EPR) effect. This effect is a consequence of the abnormal 
features of tumor blood vessels and the poorly developed 
lymphatic system, which limits drainage from tumor tissue 
(Matsumura and Maeda 1986).
However, passive targeting suffers from several limita-
tions. Targeting cells within a tumor is not always possible 
because some drugs cannot diffuse effectively, and the ran-
dom nature of the approach makes the process difficult to 
control. To overcome these bottlenecks, binding bioactive 
molecules could further improve drug targeting, and among 
these bioactive molecules are antibodies (Song et al. 2010), 
sugars (Liang et al. 2006) and peptides (Accardo et al. 2014). 
In particular, peptides offer many advantages, providing 
unlimited sequence/structure opportunities and binding 
with high selectivity and affinity to cancer-related targets. 
Furthermore, peptides possess an enhanced extravasation 
behavior, a fast diffusion tendency, and low immunogenicity 
(Langer and Beck-Sickinger 2001). They can be selected by 
screening phage display libraries, or they can be designed 
by breaking the insight 3D sequence and structure–activ-
ity relationship (SAR). More recently, numerous peptide-
decorated micelles have been formulated to target tumors 
overexpressing G protein-coupled receptors (Accardo et al. 
2014). These micelles have been characterized to deliver 
contrast agents for imaging (Accardo et al. 2004, 2013) with 
accurate physico-chemical analysis. They were tested and 
loaded with different types of poorly soluble drugs (Zhang 
et al. 2012; Jaskula-Sztul et al. 2016). Epidermal growth fac-
tor (EGF) analogs can be used as shuttle vectors to deliver 
NP-loaded drugs to tumor cells.
Nowadays, it is known that EGF plays a pivotal role in 
cell growth (Hackel et al. 1999), differentiation (McCawley 
et al. 1997) and migration (Blume-Jensen and Hunter 2001). 
Its positive signaling has been found to cause increased 
proliferation, decreased apoptosis and enhanced tumor 
cell motility and angiogenesis (Woodburn 1999). The EGF 
receptor (EGFR; also known as ErbB1 and Her1) is a trans-
membrane protein which is overexpressed in a wide variety 
of human cancers of epithelial origin, including breast, lung, 
gastric, colorectal, prostate, pancreatic, ovarian and liver 
cancers (Rocha-Lima et al. 2007). Above all, liver cancer is 
the second highest cause of cancer-related death worldwide. 
In hepatocellular carcinoma (HCC), a cancer type for which 
therapeutic options in advanced stages are quite limited, the 
over-activation of the EGF/EGFR pathway has been asso-
ciated with an aggressive phenotype, intrahepatic metasta-
sis, and poor patient survival (Bohl et al. 2002). Therefore, 
EGFR represents an important potential molecular target for 
novel therapeutic approaches to HCC.
This evidence pushed researchers, more than 10 years 
ago, to investigate the possibility of attaching EGF to 
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)/choles-
terol (Chol)/1,2-distearoyl-sn-glycero-3-phosphoethanola-
mine-N-[amino(polyethyleneglycol)-2000 (DSPE-PEG2000) 
liposomes. Biological results showed EGFR-specific cellular 
binding in cultured human glioma cells (Berasain and Avila 
2014). This useful development led to intensified efforts 
toward developing EGF peptide analogs, decorated with 
liposomes or metal NPs. A twelve-residue peptide fragment 
of EGF, referred to as GE11 (YHWYGYTPQNVI), was suc-
cessfully identified using phage display library screening (Li 
et al. 2005). Computational studies have turned this binding 
to the extracellular domain into the EGF binding pocket.
This sequence was selected to label different types of 
nanostructures, such as liposomes (Song et al. 2008), NPs 
(Cheng et al. 2011) and micelles (Liu and Chien 2015). 
The GE11 peptide was conjugated with a polyethylene gly-
col lipid (DSPE-PEG2000) and then mixed with 1,2-dio-
leoyl-sn-glycero-3-ethylphosphocholine (EPC)/Chol/
DSPE–PEG2000 preformed liposome, by following a post-
insertion method. This aggregate is able to cross membranes 
by endocytosis in vitro when mediated by EGFR overex-
pressing cancer cells (H1299 cells). In vivo, it accumulated 
in xenograft tumor tissues (Song et al. 2008). Moreover, 
compared to untargeted conjugates, the GE11 labeling gold 
NP (Au-NP)–Pc 4 showed tenfold improved selectivity for 
the glioma brain tumor. This delivery system demonstrates 
the capacity to deliver hydrophobic therapeutic cargos to 
hard‐to‐reach cancers (Cheng et al. 2011). GE11 decorated 
PLGA-PEG NPs have been reported to enhance DNA inter-
nalization within cells and to achieve higher cellular trans-
fection in cells with high EGFR expression (Liu and Chien 
2015). More recently, the co-delivery of hydrophobic doc-
etaxel (DTX) and pH-sensitive curcumin (CUR) prodrug 
has been employed for the treatment of prostate cancer (Jin 
et al. 2017).
Later, the peptide LARLLT (referred to as D4) of EGF 
was generated using computer-assisted design (CAD) (Song 
et al. 2009). This sequence binds the extracellular domain 
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I away from the EGF binding pocket. Due to the fact that 
this peptide is easier to synthesize than GE11, it was con-
jugated with DSPE-PEG2000, obtaining similar results to 
GE11 (Song et al. 2009). Moreover, small peptides that are 
able to strongly and specifically bind to EGFR are preferable 
for their minimal immunogenicity and proliferative effects. 
Recently, Vicente’s group coupled this sequence to organic 
chromophores, suggesting that it may have the ability to bind 
to cells overexpressing EGFR (Fontenot et al. 2016; Zhao 
et al. 2017). Despite these considerations in the literature, 
though, only one example of a supramolecular aggregate has 
been reported (Song et al. 2009).
In the present study, we formulated new mixed micelles 
based on PF127 by adding amphiphilic molecules function-
alized with the D4 sequence to produce a new vehicle for 
potentially shuttling hydrophobic antitumor drugs. More-
over, pluronic micelles are able to transport hydrophilic 
drugs, such as doxorubicin, to multidrug-resistant cancer 
cells (Alakhova et al. 2013). Therefore, this formulation 
is the first D4 peptide-labelled system with wide potential 
capability of reaching selected cancer cells. The active tar-
geting micelles were tested in vitro for their binding capacity 
to human HCC cell lines overexpressing EGFR.
Materials and methods
Materials
Protected Nα-(9-fluorenylmethoxycarbonyl) (Fmoc) amino 
acid derivatives, coupling reagents and Rink-amide MBHA 
resin were purchased from Calbiochem-Novabiochem 
(Laufelfingen, Switzerland). Fmoc-8-amino-3,6-dioxaoc-
tanoic acid (Fmoc-AdOO-OH) was purchased from Neo-
system (Strasbourg, France). N,N-Dioctadecylsuccinamic 
acid was synthesized according to the literature (Schmitt 
et al. 1994). All other chemicals were commercially avail-
able from Sigma–Aldrich, Fluka (Buchs, Switzerland) or 
Lab-Scan (Stillorgan, Ireland) and were used as received 
unless stated otherwise. PF127 and 1,2-dioleoyl-sn-glycero-
3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) 
(ammonium salt) (Rhod PE) were acquired from Avanti 
Polar Lipids, Inc. (Alabaster, AL, USA). All solutions were 
prepared by weight and solubilized in double distilled water.
Preparative high-performance liquid chromatography 
(HPLC) was carried out on an LC8 Shimadzu HPLC sys-
tem (Shimadzu Corporation, Kyoto, Japan) equipped with 
an ultraviolet (UV) lambda-Max Model 481 detector using 
a Phenomenex (Torrance) C4 (300 Å, 250 mm × 21.20 mm, 
5 μm) column. The column was eluted by  H2O/0.1% tri-
fluoroacetic acid (TFA) with a linear gradient elution 
of  CH3CN/0.1% TFA from 20% to 95% over 25 min at a 
20 mL/min flow rate. Liquid chromatography coupled to 
mass spectrometry (LC–MS) analyses were performed using 
Finnigan Surveyor MSQ single quadrupole electrospray ion-
ization (Finnigan/Thermo Electron Corporation, San Jose, 
CA, USA). UV measurements were performed with a 1-cm 
quartz cuvette (Hellma, Müllheim, Germany).
Peptide conjugate synthesis
Both amphiphilic peptides, (D4-(AdOO)2(C18)2 and scD4 
(AdOO)2(C18)2), were synthesized using standard solid-
phase Fmoc procedures (Carpino and Han 1972). The Rink 
amide MBHA resin (substitution 0.90 mmol/g) was used as 
the solid-phase support, and the synthesis was performed at 
a scale of 0.2 mmol. All couplings were performed once for 
1 h with an excess of 2 equivalents per single amino acid. 
Fmoc deprotection was carried out with a 30% solution of 
piperidine in dimethylformamide (DMF). When the synthe-
sis was complete, the Fmoc N-terminal protecting group was 
removed and two residues of the Fmoc-AdOO-OH linker 
and N,N-dioctadecylsuccinamic acid were sequentially con-
densed as previously reported (Accardo et al. 2007).
The amphiphilic peptide was then fully deprotected and 
cleaved from the resin with TFA and 2.0% (v/v) water and 
2.0% (v/v) using triisopropyl silane (TIS) as scavengers, at 
room temperature, and then precipitated with ice-cold water. 
The precipitate was then dissolved in a water/CH3CN (80/20 
v/v) mixture and then lyophilized. The crude peptide deriva-
tive was purified by RP-HPLC. The purity and identity were 
assessed through LC–MS analysis. The physico-chemical 
data for both peptides are reported as follows:
LARLLT D4(AdOO)2(C18)2: Rt 28.5 min; MS (ESI): 
1579.1 m/z calcd.: 1579.06 m/z [M + H+].
RTALLL scD4(AdOO)2(C18)2: Rt 29.5 min; MS (ESI): 
m/z: 1579.1 m/z calcd.: 1579.06 m/z [M + H+].
Aggregate formulation and dynamic light scattering 
(DLS) characterization
Pure PF127 micelles were prepared by weighing 20.0 mg 
of the copolymer and then adding 1.00  g of water to 
obtain an aqueous solution at 2% (w/w). Mixed PF127/
D4(AdOO)2(C18)2 and PF127/scD4(AdOO)2(C18)2 
micelles were prepared by adding 2.5% (w/w) of the amphi-
philic EGF peptide analog to PF127. The two amphiphilic 
compounds were dissolved in a small amount of MeOH/
CHCl3 (50:50, v/v). A thin film of amphiphiles was obtained 
by evaporating the solvent, slowly rotating the tube contain-
ing the solution under a steady stream of nitrogen. The film 
was hydrated (1 mL) for 5 min by vortexing, and after that it 
was used without further treatment. The same procedure was 
followed to obtain fluorescence-labeled micelles by adding 
1‰ w/w of Rhod-PE.
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The mean diameter was measured using a Zetasizer Nano 
ZS (Malvern Instruments, Westborough, MA, USA) with a 
173° backscatter detector. The other instrumental settings 
were as follows: measurement position (mm): 4.65; attenu-
ator: 8; temperature: 25 °C; cell: disposable sizing cuvette. 
The concentration of the DLS samples was 1.0 mM, and 
afterward they were centrifuged at room temperature at 
13,000 rpm for 5 min. For each batch, the hydrodynamic 
radius and size distributions were the means of three meas-
urements, and the values were calculated as the means of 
three different batches.
Cell cultures and fluorescence analysis
Four human HCC cell lines, HepG2, Hep3B, Huh7 and PLC/
PRF/5, were employed in this study. HepG2 and Hep3B 
cells were purchased from American Type Culture Collec-
tion (ATCC, Rockville, MD, USA). Huh7 and PLC/PRF/5 
cells were a gift from Prof. M. Levrero (Sapienza Univer-
sity of Rome, Italy) and Prof. O. Bussolati (University of 
Parma, Italy), respectively. Cells were cultured in RPMI 
1640 (SIGMA, Milan, Italy) containing 10% FCS (Gibco, 
Invitrogen Corporation, Carlsbad, CA, USA) and maintained 
at 37 °C at 5%  CO2. All cell lines were authenticated as 
previously reported (Augello et al. 2018).
For fluorescence analysis, HepG2 cells (20,000/well) 
and PLC/PRF/5 cells (10,000/well) were seeded in cham-
ber slides. After 24 h, cells were treated for 3 h with PF127/
D4(AdOO)2(C18)2/Rhod-PE. PF127/Rhod-PE and PF127/
scD4(AdOO)2(C18)2/Rhod-PE were used as controls. All 
aggregates were sonicated on ice for 10 min before use. 
After treatment, cells were washed 3 times with phosphate 
buffer saline (PBS) and fixed for 15 min with 3.7% para-
formaldheyde. Then, slides were mounted using Vectashield 
containing DAPI (Vector Laboratories, Inc., Burlingame, 
CA, USA) to stain cellular nuclei, and cells were observed 
using a Leica fluorescence microscope.
Western blotting and immunofluorescence
Total cell lysates were obtained using RIPA buffer (Cell 
Signaling Technologies Inc., Beverly, MA, USA). Extracted 
total proteins were used, and Western blotting analysis was 
performed, as previously reported (Cusimano et al. 2015), 
to evaluate different expression levels of EGFR in HCC 
cell lines. Rabbit polyclonal antibody (SC-120) specific for 
human EGFR was purchased from Santa Cruz (Dallas, TX, 
USA). EGFR expression levels were normalized using the 
quantified level of β-actin expression, using anti-β-actin anti-
body (SIGMA).
For immunofluorescence analysis, cells were plated in 
chamber slides and, 24 h later, cells were fixed and incubated 
for 1 h with anti-EGFR antibody. Slides were mounted using 
Vectashield mounting medium containing DAPI (Vector 
Laboratories, Inc.). Images were acquired by Leica fuores-
cence microscope.
Results and discussion
Monomer design and synthesis
The D4 sequence contains both a hydrophobic part and a 
polar amino acid. Therefore, two units of dioxoethylene 
linkers (AdOO) were introduced on the N-terminal side 
to increase hydrophilicity and maintain appropriate expo-
sure on the external aggregate surface. Two main features 
prompted the choice of ethoxyl linkers: the ability, in vivo, 
to decrease aggregate clearance, and the lack of electrical 
charges, which normally increase repulsion in the hydro-
philic shell on the aggregate surface. A hydrophobic moiety 
containing two C18 aliphatic chains was added to the sec-
ond linker to promote interactions with the hydrophobic sur-
factant moiety through van der Waals forces. The distearoyl 
moiety allows stronger interactions compared to shorter and/
or unsaturated chains. In general, the addition or insertion 
of peptide sequences onto the N-terminal moiety may alter 
its biological activity. The scrambled amino acid sequence 
RTALLL (scD4) was designed as a negative control for the 
biological assays. This sequence was selected, in turn, to 
reproduce the scrambled sequence used in the literature 
(Song et al. 2009). It is noteworthy to consider that the Arg 
residue on the C-terminus could induce a specific penetra-
tion through the membrane owing to the presence of a posi-
tive charge at physiological pH.
As previously stated, the D4(AdOO)2(C18)2 and 
scD4(AdOO)2(C18)2 (see Fig. 1) peptide derivatives were 
synthesized through solid phase methods on a Rink amide 
resin using the standard Fmoc procedure. At the end of 
monomer assembly, the two monomers were both cleaved 
using standard trifluoroacetic acid mixtures to ensure the 
complete removal of all protecting groups of the amino acid 
side chains. The crude products were purified by preparative 
reversed-phase HPLC on a C4 column and/or recrystallized 
up to a maximum final purity of 90%. Finally, they were 
isolated in 25–35% yields in lyophilized form. Their molecu-
lar masses were determined by MS ESI mass spectroscopy 
(Supplementary material).
Micelle formulation and DLS measurements
The surfactant Pluronic PF127 (see Fig. 1) was chosen for 
several reasons. The applicability of Pluronic is mainly 
driven by its self-assembly to form micelles in aqueous 
solution (Raval et al. 2017). Pluronic copolymers are potent 
sensitizers multi-drug resistant (MDR) cells that intensify 
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the cytotoxic activity of drugs. Moreover, the US Food and 
Drug Administration (FDA) has approved triblock copoly-
mer for biomedical applications. PF127 was preferred to 
other pluronics because it exhibits a longer PEO chain and 
forms micelles at room temperature. These properties allow 
researchers to use the same system to transport both hydro-
phobic and hydrophilic drugs at the same time, producing 
stable micelles suitable for in vivo application.
In physiological solution (0.9% aqueous solution in 
NaCl), micelles are produced by a hydrophobic core, com-
prising oxypropylene units, and by a hydrophilic sphere, 
made up of oxyethylene units. Peptide amphiphilic mol-
ecules were then added to obtain mixed micelles. In par-
ticular, two formulations of this supramolecular aggre-
gate were made with equal percentages (2.5% w/w) of 
D4(AdOO)2(C18)2 or scD4(AdOO)2(C18)2. Fluorescence 
aggregates were achieved by adding a modest mass amount 
(1‰) of Rhod-PE.
The choice of the amount of amphiphilic peptide added 
was suitable to guarantee a sufficient number of bioac-
tive molecule units able to interact with the receptors. The 
fact that a higher amount might have induced interactions 
between the positive charges of arginine residues present on 
peptide chains was taken into account. Moreover, amphiphi-
lic peptides might have excessively influenced the structure 
of the aggregate driven by PF127, so another aggregate 
was formulated without the bioactive molecule to use these 
micelles as a control in biological tests.
DLS measurements were performed to assess the size of 
the micelles (data are reported in Table 1). The diagrams 
show a monomodal distribution for both mixed aggregates 
(Fig. 2). In agreement with previously reported data (Basak 
and Bandyopadhyay 2013; Sharma and Bhatia 2004), the 
mean hydrodynamic diameter of the whole system at 25 °C 
provides a value of 25 nm (Table 1). The addition of both 
amphiphilic peptides increased the Gaussian distribution of 
the aggregates. The amino acid sequence did not influence 
the diameter of the mixed aggregate. Therefore, in the scD4-
labeled micelle, the positive charges on arginine are suffi-
ciently distant from the core. This issue allows us to suppose 
Fig. 1  Chemical structures of Pluronic PF127 (upper), D4(AdOO)2(C18)2 (middle), and scD4(AdOO)2(C18)2 (lower). The amino acid 
sequences of D4 and scD4 are reported in the boxes
Table 1  Structural parameters, mean hydrodynamic diameter (nm) 
and polydispersity index, (PI), obtained from DLS measurements for 
the examined systems
System Diameter (nm) PI
PF127/Rhod-PE 27.0 0.083
PF127/D4(AdOO)2(C18)2/Rhod-PE 24.4 0.25
PF127/scD4(AdOO)2(C18)2/Rhod-PE 25.0 0.20
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that the peptide chains are detached from the micelle surface 
and are able to interact with EGFRs. 
The stability of both systems in solution was verified by 
carrying out DLS measurements over 48 h while storing the 
samples at room temperature.
EGFR expression in HCC cells
The basal expression levels of EGFR were examined 
in 4 human HCC cell lines: HepG2, Hep3B, Huh7, and 
PLC/PRF/5 (Fig. 3). Three HCC cell lines exhibited dif-
ferent expression levels of the protein, with PLC/PRF/5 
cells expressing the highest levels, while HepG2 showed 
almost no expression (Fig. 3a). Western blotting results 
were confirmed by immunofluorescence analysis (Fig. 3b). 
In HepG2 cells, no evident expression of EGFR was 
observed, whereas in PLC/PRF/5, a clear cell membrane 
localization was evident.
Based on these results, for subsequent experiments, we 
chose HepG2 and PLC/PRF/5 cells as EGFR negative and 
positive HCC models, respectively.
Selectivity of PF127/D4(AdOO)2(C18)2 in binding 
to HCC cells expressing EGFR
We used fluorescence analysis to investigate the specificity 
of PF127/D4(AdOO)2(C18)2 binding to HCC cells express-
ing EGFR by taking into account the presence of Rhod-PE 
in mixed micelles. As shown in Fig. 4, after in vitro expo-
sure at 37 °C for 3 h, PF127/D4(AdOO)2(C18)2Rhod-PE 
binding to high-EGFR expressing PLC/PRF/5 cells was 
significantly higher than to EGFR-negative HepG2 cells. 
In addition, micelles decorated with a scrambled peptide 
(PF127/scD4(AdOO)2(C18)2Rhod-PE) showed no bind-
ing to HCC cells, whether positive or negative for EGFR 
expression.
These results highlighted the selectivity of the D4 pep-
tide and subsequent specificity of micelles in targeting 
EGFR-postive HCC cells.
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Fig. 2  DLS micelles a PF127/scD4(AdOO)2(C18)2 97/2,5/Rhod-PE 
(upper); b PF127/D4(AdOO)2(C18)2 97/2,5/Rhod-PE (lower)
Fig. 3  Expression of EGFR 
in HCC cell lines. a Immuno-
blotting evaluation of EGFR 
expression in four HCC cell 
lines. Equal amounts of protein 
loading were determined using 
β-actin as internal control. b 
Immunofluorescence analysis 
of EGFR protein expression in 
HepG2 and PLC/PRF/5 cells. 
Cell nuclei were stained with 
DAPI. Magnification = × 20
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Conclusion
The D4 amphiphilic peptide was prepared by conjugat-
ing an ethoxilic linker to a distearoyl tail. This monomer, 
mixed with PF127, attaches to micelles, allowing them 
to enhance EGFR binding affinity as a targeting ligand. 
The cellular binding of D4 peptide-conjugated micelles 
was more efficient in PLC/PRF/5 cancer cells overexpress-
ing EGFR than in HepG2 tumoral cells with low EGFR 
expression. Moreover, in cells highly expressing EGFR, 
the D4-conjugated micelles exhibited higher cellular bind-
ing than the D4 scrambled peptide-labeled micelles. These 
results allowed us to demonstrate that the N-terminal moi-
ety of the sequence can be modified and conjugated to eth-
oxilic linkers without losing receptor affinity. Moreover, 
although PF127 endows a long PEO chain, it does not hide 
the peptide sequence that is well-exposed on its hydro-
philic shell. The low uptake of the scrambled peptide con-
firms that the interaction with the receptor is not driven by 
random contacts between amino acids. All of this experi-
mental evidence led us to conclude that these aggregates 
can be loaded with hydrophobic and/or hydrophilic drugs, 
and they can deliver their payload selectively to cancer 
cells. Further perspectives are very promising due to the 
broad range of applications for drugs nanocarriers. They 
can be loaded with specific drugs, either conventional 
chemotherapy (such as doxorubicin, paclitaxel and cispl-
atin.) or molecular targeted agents (such as erlotinib and 
sorafenib.) which have been used as antitumor agents in 
different cancer types, including HCC.
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Fig. 4  Fluorescence micros-
copy images of HepG2 
and PLC/PRF/5 cells after 
in vitro exposure to PF127/
D4(AdOO)2(C18)2/Rhod-
PE (4.0 mg/0.1 mg/6 × 105 
Rho-PE mol) or PF127/
scD4(AdOO)2(C18)2/Rhod-PE 
(4.0 mg/0.1 mg/6 x  105 Rho-PE 
mol) at 37 °C for 3 h. Images 
from left to right show: cell 
nuclei stained with DAPI (blue); 
fluorescent micelles bound to 
cells (red); overlays of the two 
images (merge). Magnifica-
tion = × 20
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